Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.

ABSTRACT:

Introduction

Advancements in chemotherapy treatment have improved the clinical management of metastatic colon cancer (mCC) patients. An increasing number of elderly mCC patients receive various combinations of regimens in second-line chemotherapy/biologics treatment (Tx2) after first-line treatment (Tx1) to prolong survival and/or palliate symptoms, but these regimens have higher costs. This analysis investigated the survival benefit and incremental cost associated with Tx2 among elderly mCC patients.

Methods

Elderly (aged ≥66 years) SEER-Medicare patients diagnosed with mCC in 2003-2007 were identified and followed until death or the end of 2009. Cox regression and partitioned least squares regression were utilized to obtain the survival benefit and incremental cost associa

SUBMITTER: Zheng Z 

PROVIDER: S-EPMC4115177 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature